Neurona Therapeutics

Neurona Therapeutics is a pioneering cell therapy company focused on repairing dysfunctional neural circuits underlying chronic neurological diseases. Its core technology involves creating off-the-shelf, allogeneic neural cell therapies, with its lead program, NRTX-1001, advancing toward a pivotal Phase 3 trial in focal epilepsy in 2026. Founded in 2008 and based in South San Francisco, the private company is positioned at the forefront of regenerative neurology, targeting large, underserved patient populations with high unmet need. Its approach represents a paradigm shift from symptom management to potential one-time, disease-modifying treatments.

Platform for deriving allogeneic, off-the-shelf neural cell therapies (inhibitory neurons, other neuronal subtypes, glial cells) from human pluripotent stem cells for targeted repair of dysfunctional neural circuits.

Neurona is a pioneer in allogeneic inhibitory neuron cell therapy for epilepsy, with a clear lead in clinical development. Competition exists from other cell therapy approaches (e.g., autologous cell therapies, different cell types), gene therapies, and neuromodulation devices. However, its specific mechanism and advanced clinical stage give it a distinct competitive position in regenerative neurology.